Further evidence adds to already strong set of positive clinical data Data presented at ECTRIMS 2019 Congress in Stockholm, Sweden Geneva, Switzerland, September 16, 2019 – 7:30 am CEST – GeNeuro (Euronext Pari ...
Setanaxib (GKT831) achieved statistical significance (p=0.02) for primary endpoint with the 400mg BID versus placebo, after correction of nonnormal distribution (outliers) in 400mg OD In advanced patients, setanax ...
World Health Organization (WHO) recognized GKT831 as first representative of NOX inhibitor therapeutic class The recommended new stem “naxib” recognizes NOX inhibitors as a new therapeutic class The NOX inhibit ...
Study expands potential clinical indications for lead compound Trial fully funded via a grant from the United States National Institutes of Health Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) ...
Human Endogenous Retroviruses linked to MS, Type 1 diabetes, ALS, schizophrenia GeNeuro’s temelimab most advanced drug candidate targeting pathogenic HERV Geneva, Switzerland, 11 July 2019 – 6:00pm CEST – GeNe ...
DATA SUPPORTS THERAPEUTIC ROLE OF GKT831 IN ADVANCED LIVER FIBROSIS Results published in Clinics and Research in Hepatology and Gastroenterology Phase 3 trial being planned in primary biliary cholangitis Genky ...
